Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis

摘要

Key Clinical Message Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV‐related vasculitis and may evade the need for dialysis as in our patient.